Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

Chardan Capital analyst Geulah Livshits has maintained a Buy rating on Palvella Therapeutics (NASDAQ: PVLA) and increased the price target from $210 to $240.